Senores Pharma Q1 FY27 Revenue Up 36% to ₹180 Cr; Appoints Anjali Shah as SMP
Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹180 crore, a 36% YoY increase. PAT grew 56% to ₹31.20 crore, with EBITDA up 87% to ₹54 crore. The company appointed Ms. Anjali Shah as Senior Management Personnel (SMP) effective July 27, 2026.
The financial results show significant growth, which is positive for investors. The appointment of SMP is an important operational event but does not dramatically alter the company's strategic direction on its own.
The company reported strong year-on-year growth in revenue and profitability, along with positive commentary on future outlook and business expansion. The appointment of a new SMP is a standard corporate event.
Senores Pharmaceuticals Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company's consolidated revenue grew by 36% year-on-year to ₹180.21 crore. EBITDA increased by 87% to ₹54 crore, with a margin expansion of approximately 800 basis points. Profit After Tax (PAT) rose by 56% to ₹31.20 crore.
The company reported strong performance across its business segments, with Regulated Markets revenue growing by 41.9% to ₹127.8 crore and Emerging Markets revenue increasing by 29.6% to ₹37.6 crore. The Regulated Markets portfolio saw significant expansion, with approved ANDAs growing from 30 to 58, of which 23 have been commercialized.
In a significant management update, the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Ms. Anjali Shah, Assistant Vice President - Finance, as Senior Management Personnel (SMP) with effect from July 27, 2026. Ms. Shah is a qualified Chartered Accountant with over 10 years of experience in finance, taxation, and financial reporting.
The Board meeting commenced at 01:45 PM IST and concluded at 02:55 PM IST on July 27, 2026.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.